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HemagglutininBeta-propiolactone (BPL) is commonly used as an inactivating reagent to produce viral vaccines. Although BPL
has been described to chemically modify nucleic acids, its effect on viral proteins, potentially affecting viral
infectivity, remains poorly studied. Here, a H3N2 strain of inﬂuenza virus was submitted to treatment with
various BPL concentrations (2–1000 μM). Cell infectivity was progressively reduced and entirely abolished at 1
mM BPL. Virus fusion with endosome being a critical step in virus infection, we analyzed its ability to fuse with
lipid membrane after BPL treatment. By monitoring calcein leakage from liposomes fusing with the virus, we
measured a decrease of membrane fusion in a BPL dose-dependent manner that correlates with the loss of
infectivity. These data were complemented with cryo transmission electron microscopy (cryoTEM) and cryo
electron tomography (cryoET) studies of native and modiﬁed viruses. In addition, a decrease of leakage
irrespective of BPL concentration was measured suggesting that the insertion of HA2 fusion peptide into the
target membrane was inhibited even at low BPL concentrations. Interestingly, mass spectrometry revealed that
HA2 and M1 matrix proteins had been modiﬁed. Furthermore, fusion activity was partially restored by the
protonophore monensin as conﬁrmed by cryoTEM and cryoET. Moreover, exposure to amantadine, an inhibitor
of M2 channel, did not alter membrane fusion activity of 1mM BPL treated virus. Taken together these results
show that BPL treatment inhibits membrane fusion, likely by altering function of proteins involved in the fusion
process, shedding new light on the effect of BPL on inﬂuenza virus.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Infectionswith inﬂuenza viruses cause recurrent epidemics and global
pandemics. Seasonal infection is estimated to cause between 250,000 and
500,000 deaths. Moreover, the 2009 pandemic was responsible for more
than 250,000 deaths. In addition, these outbreaks have major economic
consequences in terms of absenteeism, treatment and hospitalization
costs. In the USA alone, this loss is estimated to be about $27 billion per
year. The high capability of antigenic shift leads to the emergence of
novel viruses, against which acquired immunity by previous inﬂuenza
infection or vaccination is poorly efﬁcient. Biotechnological improve-
ments relying on genetic, structural, functional and chemical studies are
required for thedevelopment of better viral treatments andmore efﬁcient
vaccines to ﬁght against present and future inﬂuenza virus variants.
The main targets of the inﬂuenza virus are epithelial cells of the
respiratory tract. The outer surface of the virus [1] exposes the trimeric, Université Bordeaux, Institut
600 Pessac, France. Tel.: +33
mbert).
ights reserved.transmembrane glycoprotein hemagglutinin (HA) required for viral
binding to sialic acid moieties on the surface of host cells [2] which
initiates membrane fusion (for reviews, see [3–6]).
Each monomer of HA consists of two disulﬁde-linked subunits, HA1
and HA2. HA2 contains a transmembrane domain at its C-terminus side
and at its N-terminus, the “fusion peptide,” an amphiphilic stretch of
amino acids which is buried in the HA stem at neutral pH [7]. HA1
monomers contain at the membrane-distal tip of the trimer, a receptor
binding pocket composed of highly conserved amino acids (Tyr98,
Ser136, Trp153andHis183) that bind sialic acidmoieties viahydrophobic
interactions or hydrogen bonds [2,8]. Once the cell membrane and the
virus have been closely juxtaposed by virus–receptor interaction, the
complex is internalized by endocytosis through a clathrin dependent
pathway. Upon acidiﬁcation of the interior of the endosome, the viral
HA undergoes irreversible conformational rearrangements involving
extrusion of the fusion peptide from the HA stem [9] toward the target
endosomalmembrane [10–13], and transformation of theHA loop region
into a large coiled coil domain [9] triggering apposition and fusion of viral
and endosomal membranes [12,14,15]. As a consequence of viral interior
acidiﬁcation arising fromH+ transport through theM2 channel, the viral
Ribo-Nucleo-Protein complexes (vRNPs) dissociate from M1 matrix
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vRNPs are then imported into the nucleus for transcription, translation
and ﬁnally virus ampliﬁcation [16,17].
Currently, two forms of inﬂuenza vaccine are available for
widespread distribution: inactivated vaccines and live-attenuated
vaccines. Preparation of inactivated vaccines consists of several
steps: (i) virus of a chosen subtype is propagated in embryonated chicken
eggs, (ii) the virus is puriﬁed (iii), inactivatedwith formaldehyde or beta-
propiolactone (BPL), (iv) the inactivating reagents are removed and
(v) the virus is split with detergent. To prepare the vaccine, various
subtypes of inﬂuenza A (H3N2 and H1N1) as well as inﬂuenza B are
then mixed to provide a broader range of protection against seasonal
circulating viruses. Interestingly, the choice of virus inactivation
procedure is then of great importance to effectively protect against
infection. Indeed a recent report showed thatwhole inactivated inﬂuenza
virus with beta-propiolactone (BPL) provided a better protection against
different virus subtypes than split or formaldehyde-inactivated virus [18].
BPL is widely used for the inactivation of infectious agents (bacteria,
fungi, viruses) in many vaccine preparations as well as in disinfection,
plasma sterilization and tissue transplants [19–23]. This very widespread
industrial use of BPL contrasts somehow with the limited knowledge
available on the molecular consequences of its action. BPL reacts with
nucleophilic reagents (including nucleic acids and proteins) leading to
alkylated and/or acylated products. BPL is very reactive with different
chemical moieties of various biological molecule including proteins
(mostly methionine, cysteine and histidine) and nucleic acids (mainly
adenosine, cytidine and guanosine moieties of the vRNA) [24–26]. BPL
alters the capability of DNA to be used as template by polymerase [22].
From literature, the effect of BPL is dose and specimen -dependent. In
the presence of 2mM BPL infectivity of plasmid pUC18 is reduced while
no effect was observed at 250 μM BPL [22]. At 250 μM, BPL drastically
inhibits the infectious activity of phage M13 [22]. BPL seems to be more
effective in inactivating enveloped viruses than non-enveloped viruses
[23]. Interestingly, BPL use appears also suitable to obtain a speciﬁc
immunity against respiratory syncytial virus and H5N1 virus [18,27].
BPL treatment then mediates a loss of infectivity while maintaining
antigenicity. This effect has been obtained for high BPL doses more than
several millimolars. These results are promising for the use of BPL in
vaccine preparation. However regarding WHO and European Pharma-
copoeia recommendations, a better ﬁne-tuning of BPL doses is required
for industrial vaccine production processes to assure viral inactivation.
There is a limited understanding of the relation between molecular
modiﬁcation and loss of infectious titer as well as the capacity of BPL
to modify proteins. That limits the BPL use for preparing safe vaccines.
This lack of knowledge is likely at the origin of “over inactivation” and
inappropriate reaction.
In the present work, we aimed at establishing the effects of viral BPL
treatment at a molecular level and thus to close this existing gap of
knowledge and to study in particular the effect of this inactivating
agent on viral proteins. Virus samples of the H3N2 strainwere submitted
to various doses of BPL. This strain is part of the seasonal inﬂuenza virus
produced at industrial scale. In addition, the BPL inactivation procedure
employed in this study is identical to that used to produce the
commercial vaccine. The infectivity of BPL-treated virus was found to
be reduced in a BPL dose-dependentmanner. By combining ﬂuorescence
spectroscopy, mass spectrometry, cryo transmission electronmicroscopy
(cryoTEM), and cryo electron tomography (cryoET), we observed that
BPL-treated viruses had lost their capacity to fuse with liposomes in
dose dependent manner.
2. Materials and methods
2.1. Chemical products
Egg phosphatidylcholine, N-(lissamine rhodamine B sulfonyl)-
phosphatidylethanolamine (N-Rh-PE) N-(7-nitro-2,1,3-benzoxadiazol-4-yl)-phosphatidylethanolamine (N-NBD-PE) and GM3 gangliosides
were purchased from Avanti Polar Lipids Inc. (Alabaster, Al), monensin
from Calbiochem, cholesterol, Porcine trypsin, and amantadine from
Sigma-Aldrich (St Louis, MO).
Ultrapure water with a nominal resistance of 18 mΩ cm (Milli-Q,
Millipore) was used for all buffers and solutions. All other chemicals
were purchased of the highest purity available from Sigma-Aldrich.
2.2. Liposome preparation
Multilamellar vesicles (MLV) were produced by resuspension of dry
lipid ﬁlms of egg phosphatidylcholine, cholesterol, ganglioside GM3 at a
molar ration of 8:1:1 in a buffer A (150mMNaCl, 5mMHEPES pH7.4, 1
mM EGTA). The MLV suspension was then quickly frozen in liquid
nitrogen and thawed (water at 37 °C) ﬁve times. MLV suspension
was then forced through 0.1 μm deﬁned pore polycarbonate ﬁlters
(Whatmann) using a manual extruder (Avanti Polar lipids) to form
large unilamellar vesicles. Phospholipid phosphate concentration was
determined according to Böttcher et al. [28].
2.3. Inﬂuenza virus preparation and BPL inactivation
An egg-grown inﬂuenza virus preparation (A/Victoria/210/2009 —
H3N2) was obtained from clariﬁed allantoic ﬂuid and puriﬁed on a
sucrose gradient. All virusworkwas carried out at 4°C. Viral preparations
were dialyzed over night into phosphate buffer saline (PBS) at pH7.5 and
protein concentrations determined using Bradford protein reagent
(BioRad) was adjusted to 2 mg/mL. Four viral preparations were
inactivated using different BPL concentrations [22,23,29,30]. In brief,
sodium phosphate at a ﬁnal concentration of 100 mM was added to
prevent pH changes that occur with the addition of the desired (2, 20,
250 and, 1000 μM) BPL concentration. Samples were incubated with
gentle stirring overnight at 4 °C. Preparations were then again dialyzed
24 hours against PBS at 4 °C. The viral protein concentration was again
determined prior to conducting further experiments. Samples were
stored at 4 °C with 0.01% (w/v) sodium azide and used within two
months.
2.4. TCID50 assay
MDCK cells were seeded in 96 well plates at a density of 3.75×104
cells/well in DMEM (Gibco®) supplemented with 1 μg/mL porcine
trypsin. Cells were infected with 50 μL of tenfold serial dilutions of
virus and incubated for 4 days, at 37 °C. Supernatants from these
cultures were then tested in a hemagglutination assay. TCID50 titers
were calculated according to the method of Spearman–Karber [31].
2.5. Hemagglutination assay
The HA hemagglutination assay was performed by serially diluting
50 μL of culture supernatants 2-fold with PBS in V-bottom plates.
Subsequently, 50 μL of 0.5% chicken red blood cells (Sanoﬁ Pasteur,
Alba-la-Romaine, France) were added to each well. The plates were
incubated for 1 h at 4 °C and the hemagglutination or the absence of
hemagglutination was determined visually for each well.
2.6. SDS-PAGE and mass spectrometry analysis
1mM BPL-treated virus (15 μg proteins) were deglycosylated with
PNGase F, denatured in XT sample buffer (Bio-Rad) under reducing
conditions, and separated on a Criterion XT 4–12% Bis-Tris gel (BioRad)
in MOPS-XT buffer. The gel was ﬁxed in 50% (v/v) methanol, 7% (v/v)
acetic acid for 30min and stained using GelCode. The gel was rinsed in
distilled water. Excised gel bands of interest were washed alternatively
with 50mM ammonium bicarbonate pH 8.0 and acetonitrile. Proteins
were then reduced with 10 mM DTT, alkylated with 55 mM
Fig. 1. Infectivity of A/Victoria/210/2009 (H3N2) inﬂuenza virus after treatment with
various concentrations of BPL, i.e., 2, 20, 250 and 1000 μM. 100% infectivity represents
native virus.
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at 0.01mg/ml diluted in ammoniumbicarbonate 25mMbuffer. Digestion
was not stopped by 0.1% TFA. Samples were then deposited on a matrix
layer of α-cyano-4-hydroxycinnamic acid (HCCA) saturated solution
in 50% acetonitrile and 0.1% TFA. Analyses were performed on an
Ultraﬂextrem MALDI-TOF-TOF mass spectrometer in reﬂectron positive
mode (Bruker Daltonics, Billerica, MA). External calibration was done
using peptide calibrants (Bruker Daltonics, reference 222570). Mass
spectra were acquired using sets of instrument parameters over them/z
300 to 5000. MS/MS analysis was performed on peptides of interest.
Spectra analysiswas performedwith FlexAnalysis and Biotools softwares.
2.7. Membrane fusion measurements
Membrane fusion between virus and labeled liposomes was
performed with a Förster Resonance Energy Transfer (FRET) assay
[32]. Labeled liposomes, prepared as described above, from a lipid ﬁlm
containing 0.6 mol% each of N-Rh-PE and N-NBD-PE. Fusion was
measured at room temperature in buffer B (135 mM NaCl, 15 mM
sodium citrate, 10 mM MES, 5 mM HEPES, 1 mM EGTA at pH 5.1) at
excitation and emission wavelengths of 465 and 530 nm, respectively.
For calibration of the ﬂuorescence scale, the initial residual ﬂuorescence
intensity was set to zero and the intensity at inﬁnite probe solution
100%. The latter value was obtained after lysis of the liposomes with
Triton X-100 (0.5% v/v) with correction for the quenching of NBD by
Triton X-100 [33]. Concentrations for liposome and virus correspond
to their lipid concentrations which were 2.5 μM and 5 μM respectively
and calculated as follows. For liposome, lipid concentration was
estimated from phosphorus determination as detailed in liposome
preparation section. For virus, lipid concentration was estimated from
the Bradford determination using the lipid to protein ratio equal to 0.5
and a lipid MW of 800 Da. Membrane fusion kinetics in the presence
of amantadine and monensin were monitored at 37 °C [34,35]. Before
measurement, virus was incubated at room temperature for 30 min
with either 1 μM of monensin (ﬁnal concentration) 10, and 50 μg/mL
of amantadine (ﬁnal concentration). Because conformational changes
of HA are faster at 37 °C than at room temperature, liposomes and
virus concentrations were 7.5 μM and 15 μM respectively. For cryoTEM
observations of the “monensin experiments,” viruses and liposomes
were incubated 3minutes at 37 °C at pH5.1 before vitriﬁcation.
2.8. Leakage measurements
Calcein encapsulating liposomes were prepared as described
previously [12]. Brieﬂy, calcein was entrapped into liposomes by
hydrating the dry lipid ﬁlm in isotonic buffer containing 75mM calcein.
After extrusion as described above, free dye was removed by molecular
sieve chromatography on Sephadex G75 with buffer A. An increase in
calcein ﬂuorescence by dilution of self-quenched ﬂuorescent dye due to
fusion or direct leakage from liposomes was assessed by monitoring
calcein ﬂuorescence at 515 nm with excitation at 485 nm on a Perkin-
Elmer LS55 spectroﬂuorimeter. These measurements were carried out
at room temperature in buffer B. Data were normalized by setting initial
ﬂuorescence intensity of calcein-loaded liposomes to zero and the
intensity of full dequenched calcein (obtained after lysis of LUV with
triton X100-0.5% v/v) to 100. Liposomes and virus concentrations were
respectively 2.5μM and 5μM.
2.9. CryoTEM and CryoET
A 5 μL sample was deposited onto a lacey carbon cupper grid (Ted
pella) placed in the automated device for plunge-freezing (EM GP
Leica) enabling a perfect control of temperature and relative humidity
for experiment performed at 25 or 37 °C respectively. The excess of
sample was blotted with ﬁlter paper and the grid was plunged into a
liquid ethane bath cooled and maintained at −183 °C with liquidnitrogen. Specimensweremaintained at a temperature of approximately
−170 °C, using a cryo holder (Gatan, CA, USA) and observed with a FEI
Tecnai F20 electron microscope operating at 200 kV and at a nominal
magniﬁcation of 29,000× under low-dose conditions. Images were
recorded with a 2k×2k USC 1000 slow-scan CCD camera (Gatan).
For cryoET, tilt-series were collected automatically on FEI Tecnai F20
from −60° to +60° with 1° angular increment at a nominal 8 μm
defocus using the UCSF tomography software [36]. Images were
recorded on CCD camera with a 3.7 Å pixel size at the specimen level.
Alignments of tilt series binned by a factor of two were performed
with the IMOD software [37] using 10 nm colloidal gold particles as
ﬁducial markers. Tomographic reconstructions were calculated by
weighted back-projection using Priism/IVE package [38]. Final voxel
size was 7.4 Å. Semi-automatic segmentation of Fig. 3C was carried
out by applying one cycle of median 6 × 6 × 6 ﬁlter, a background
subtract, and a threshold according to the Otsu scheme using ImageJ
(Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda,
Maryland, USA, http://rsb.info.nih.gov/ij/, 1997–2009). Tomogram
renderingwas calculatedwith the UCSF Chimera package fromResource
for Biocomputing, Visualization, and Informatics at the University of
California, San Francisco (supported by NIH P41 RR001081) [39].
3. Results
3.1. BPL treatment reduced irreversibly viral infectivity on host cells
The infectivity of viral samples previously treated with different
concentrations (2, 20, 250 or 1,000 μM) of BPL was measured in cell
culture (Fig. 1). Viruses treated with 2 μM BPL lost about 50% of their
cell infectivity compared to native virus. With higher doses (10- and
125-fold), viruses lost their infectivity almost completely and treatment
with 1 mM BPL caused complete suppression of infectivity. The ID50
(effective BPL dose) was estimated at 3 μM in a 95% conﬁdence limit.
Moreover, a comparable loss of infectivity wasmeasured for inactivated
viruses stored at 4 °C for two and seven months after inactivation
indicating that the BPL effect was irreversible over this period of time
(data not shown). In addition H1N1 inﬂuenza virus (A/Brisbane/59/
2007 genotype) submitted to the same doses of BPL exhibited a similar
loss of infectivity as the H3N2 virus suggesting comparable sensitivities
of different viral strains to BPL treatment (Fig. S1).
3.2. Viral membrane fusion inhibited by BPL treatment
A crucial step in the infection process is membrane fusion with
endosome. We studied the membrane fusion activity of various BPL-
treated viruses with liposomes at low pH using a FRET assay according
to a well established protocol [40]. Results of treated and native viruses
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Fig. 2. BPL effect on virus membrane fusion and on calcein leakage. A) BPL-treated and
native viruses were incubated with [N-NBD-PE/N-Rh-PE] - labeled liposomes containing
GM3 gangliosides. Membrane fusion was measured with a FRET assay for various BPL
doses at pH 5.1. B) BPL-treated and native viruses incubated with calcein-loaded GM3
liposomes. Dequenching of ﬂuorescent probes due to calcein leakage arising from HA
fusion peptide insertion in target membrane was measured for various BPL doses at pH
5.1 and room temperature. a, b, c, d and e correspond to 0, 2, 20, 250 and 1.000 μM BPL
treated virus respectively. As control experiment, native virus incubated with GM3
liposomes at pH7.4 is presented in f. C) Infectivity versus Initial rate of membrane fusion
for the BPL treatment conditions. A linear regression could be ﬁtted within the range of 0
to 250 μM BPL corresponding to ‘a’ to ‘d’ in A). 1,000 μM BPL condition (‘e’ in A)) was
excluded from the linear regression.
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found to level off after approximately 12 minutes corresponding to
about 45% increase in ﬂuorescence. This level of FRET was in good
agreementwith results previously obtained on comparable H3N2 strain
[12]. The membrane fusion activity decreased steadily with increasing
BPL concentration. Both the ﬁnal level and the initial rate of fusion
were lowered suggesting that the number of fusion events is reduced
and also that the fusion mechanism is impaired by BPL treatment.
Although BPL treatment did not totally inhibit the membrane fusion
activity even at the highest doses, the FRET experiments showed that
this inhibition is a BPL dose-dependent process suggesting that one or
more proteins involved in this mechanism have their functions altered
by BPL.
3.3. Effect of BPL treatment on calcein leakage
HA protein is involved at different levels of the membrane fusion
process. The N-terminal fusion peptide of the HA2 subunit undergoes
a conformational change triggered by the pH decrease leading to its
insertion into the target membrane [10–12,41]. This process was
monitored by spectroﬂuorometric measurement of calcein escape, a
small negatively charged ﬂuorescent molecule entrapped in liposomes
and self-quenched at high concentration. Its leakage from the internal
volume of liposomes was induced by the penetration of viral fusion
peptide within the target lipid membrane [42,43]. Fusion peptides
perturbing locally the target membrane triggered calcein release from
liposomes leading to a strong increase of ﬂuorescence [12]. Native and
BPL-treated viruseswere incubated at pH5.1with liposomes containing
entrapped calcein (Fig. 2B). Native and BPL-treated viruses exhibited
high calcein leakage activity. Calcein escape was massive for native
virus (close to 62%) and in a range of 35% to 45% for all BPL-treated
virus (100% corresponding to full dequenched calcein). Calcein leakage
was signiﬁcantly reduced for BPL-treated virus compared to native
virus. Following treatment with 2 μM BPL, a leakage of 37% was
measured, revealing that the process efﬁciency was already slowed
down at low BPL treatment. For treatments with higher BPL concen-
trations, we observed that the decrease of molecule leakage was not
related to BPL doses, unlike themembrane fusion process. These results
suggest that BPL treatment leads to the inactivation of someHAproteins
whereas others remain functional. The similarities of the initial kinetic
rates suggest that the number of functional HA proteins is not a rate-
limiting parameter at the beginning whereas the early onset of the
ﬂuorescence leveling off may represent the lack of functional HA
species.
3.4. Membrane fusion of native and BPL-treated viruses with liposomes
observed by cryoTEM and cryoET
At pH 7.4, the overall aspects of BPL-treated and native viruses are
very similar. BPL-treated or native viruses were observed in contact
with liposomes containing GM3 gangliosides (Fig. S2). At low pH,
cryoTEM revealed that the surface of native viruses was fuzzy showing
that HA glycoproteins have lost their well deﬁned shape (compared to
the rod shape at the neutral pH condition) due to their low pH
conformational changes (Fig. 3).Moreover, a large number of liposomes
appeared to be in close contact with viruses (Fig. 3A–B). Depending on
their deformation at the viral surface, we classiﬁed liposomes into three
different groups, named intact liposomes (I), liposomes exhibiting a
peculiar funnel-like shape (II) and virus-fused liposomes (III) (Fig. 3B).
Using cryoET, we were able to get further structural information of
liposome groups I and II (Fig. 3C–G). On three extracted Z-slices from
the tomogram, enabling the visualization of upper, equatorial and
lower part of viruses, liposomes I appeared in close interaction with
glycoproteins, while maintaining their spherical shape and membrane
continuity (Fig. 3C). Unlike liposomes of group I, the lipid membrane
of group II liposomes was disrupted at the contact zone with the virus(arrow Fig. 3C) and formed a 12 nm hole as shown in Fig. 3C (arrow).
The zone of this membrane hole interacted with protein densities of
the virus which corresponds to a typical fusion intermediate step
named “protein pore” according to Lee [15]. Liposomes of group III
revealed glycoproteins at the surface of liposomes covering partially
themembrane surface, strongly suggesting that such complex structure
II
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Fig. 3. CryoTEM and cryoET of native virus incubated with liposomes at pH5.1. A) Typical images of native virus interacting with liposomes revealing different steps of viral membrane
fusion process correspond to intact liposome interacting with virus (I), ruptured liposome (II), B) typical image of product of viral membrane fusion (III). These steps correspond to
early, intermediate and late steps of viral membrane fusion process. C–G). Liposomes I and II analyzed by cryoET. C) Stereoscopic view of isosurface showing liposomes (I and II) colored
in green, purple, blue surrounding the virus (gray color). D) Isosurface of tomogram portion and three Z-slices (Z=131 (E), Z=92 (F) and Z=80 (G)) extracted from the tomogram
showing liposomes I and II. For the sake of clarity, the contrast was inverted in the tomogram. Note the ruptured lipid membrane II in contact with glycoprotein densities (arrow in F)
which forms a 12 nm circular pore (arrow in D). Scale bars are 50 nm.
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cryoTEM images revealed virus–liposome complexes trapped in the
early, intermediate and late steps of the viral membrane fusion process.
BPL-treated viruses were observed under the same conditions to
assess structural alterations caused by BPL treatment. The same liposome
classiﬁcationwas carried out (see Table S2 for liposomedistribution) and
the most advanced events of viral membrane fusion process were
presented in Fig. 5. Viral samples treated with 2 μM BPL interacted with
liposomes leading to complete fusion events i.e. liposome (III) (Fig. 4A).
At elevated BPL concentrations the cryoTEM analyses revealed that
deformed liposomes (II) were still present. No complete fusion eventwas encountered, which contrasts somehow the above reported FRET
measurements, in which clearly residual fusion events were observed
at the same BPL concentration. It may be hypothesized that this level
of membrane fusion events seems too low for their observations by
cryoTEM and may be a potential cause for these differences. These
cryoTEM observations were thus indicative of the efﬁciency of
membrane fusion process and were in good agreement with FRET
measurements. All together these results provided evidence that BPL
treatment impaired virus fusion in a dose dependent manner (Fig. 4B–
D). We have observed that the function of HA molecules is altered.
According to leakage measurements, BPL treatment has an effect on
360 P. Bonnafous et al. / Biochimica et Biophysica Acta 1838 (2014) 355–363HA molecules by preventing the fusion peptide insertion. But all HA
molecules are not concerned by this preclusion. Some HA molecules
remained fully functional irrespectively to BPL doses. Thus, the dose-
dependent inhibition of membrane fusion should involve another
protein than HA. But also, this ﬁnding raises the question of whether
the membrane inhibition is related to protein modiﬁcations.3.5. BPL treatment modiﬁed viral assembled proteins
In order to evaluate whether BPL reacts with virus-assembled
proteins, mass spectrometry (MS) has been used to monitor protein
modiﬁcation following treatment with 1mMBPL. After deglycosylation
and SDS-PAGE electrophoresis, proteins were submitted to trypsine
digestion followed by MALDI-TOF mass spectrometry. Three peptides
have been unambiguously identiﬁed from HA2 subunit and M1 matrix
proteins (Table 1). One molecule of BPL reacted with Lys68 and
Lys143 for HA2 subunit and with Glu152, Asp156 or His159 for M1Fig. 4. Typical cryoTEM images of BPL-treated virus incubated with liposomes at pH 5.1.
A) At 2 μM BPL, liposomes (I), (II) and (III) were observed. B, C) At 20 and 250 μM BPL
respectively, only liposomes (I) and (II) were encountered. D) At 1,000μMBPL, liposomes
(I) were present while liposome (II) was scarcely observed. Annotations I to III are
described in Fig. 3. Scale bar is 50 nm.matrix protein. Interestingly, the targeted Lys68 ofHA2 is locatedwithin
a loop of HA stem core at neutral pH. At low pH this loop adopts a helical
structure triggering the exposure of fusion peptide at the coiled coil
top [9]. This conformational change might be affected by this BPL
modiﬁcation. For HA1 and vRNP, peptide modiﬁcations were not
observed. Because MALDI-TOF is not a quantitative method, it is difﬁcult
to concludewhether these twoproteins remain intact.We have not been
able to analyze Neuraminidase and M2 protonophore due to a low
number of copies present in the virus. These MS results demonstrated
that BPL reacted with viral assembled proteins suggesting that this
membrane inhibition would be due to functional blocking of some
proteins because of their chemical modiﬁcation. Inactivation of HA
could be caused by the modiﬁcation of amino acids (Lys68 and 143) of
HA2. Membrane fusion being a multistep process involving several
proteins, we further explored how the acidiﬁcation process and M1
dissociation is disturbed by BPL.3.6. Membrane fusion of native and BPL-treated viruses with liposomes
enhanced by addition of monensin
The increase of H+ concentration causes irreversible conformational
changes of HA, a prelude to the formation of fusion pore andmembrane
fusion. Concomitantly, the acidiﬁcation of the interior of the virus is
required for triggering M1-vRNPs dissociation that might facilitate
membrane fusion [16,17]. The M2 protonophore is responsible for this
H+ internalization. Monensin is a polyether antibiotic that acts as a
Na+/H+ ionophore by forming stable complexes with monovalent
cations, able to enhance membrane fusion at 37 °C [34,35]. Virus
suspension was incubated with 1 μM monensin for 15minutes at pH 7
and mixed with liposome suspension at pH 5.1, the FRET kinetics
being recorded at 37 °C (Fig. 5A). In the presence of monensin, native
virus exhibited a more efﬁcient membrane fusion activity compared to
control measurement (Fig. 5A). Initial rates were signiﬁcantly increased
and theﬂuorescence intensity at theﬁnal levelwas enhanced (from40%
to 53%). These results were in perfect agreement with data reported
previously [34,35]. Monensin had a similar effect on virus treated with
1 mM BPL. Membrane fusion activity was superior both in term of
intensity and initial rate (Fig. 5A). Monensin enabled the restoration of
membrane fusion activity of BPL-treated virus that is dependent on
the level of proton inﬂux controlled by M2 channel. Of note, the fusion
activity for BPL-treated virus in the presence of monensin did not
reach a level comparable to those measured with native virus since
BPL also inhibited by the fusion peptide insertion into the target
membrane.
CryoTEM of BPL-treated viruses incubated with monensin were
carried out under similar conditions (Fig. 5B). Several complete mem-
brane fusion events (liposomes (III)) were encountered and fully
conﬁrmed FRET data that monensin has restored the membrane fusion
activity of BPL-treated virus. These events resembled those observed
with native virus at the same temperature (data not shown). To get
further structural details on these fusion events, cryoET was performed
on a liposome (III) (Fig. 5C). As a proof of a product of fusion between a
virus and a liposome, this liposome (III) contained an internal vesicle
genuinely present before virus fusion (Fig. 5C, D). Sequential Z-slices
extracted from tomogram, revealed glycoprotein densities distributed
unevenly at the surface of the lipid membrane in good concordance
with previous observation [44]. These glycoproteins exhibited globular
mass linked to the membrane through a thin tail, likely corresponding
to HA [45]. The matrix formed a dense structure detached from lipid
membrane. As previously observed with ﬁlamentous virus [45], the
M1matrix proteins form a compact structure and are not disassembled
into individual molecules after fusion. Although it was difﬁcult to
identify vRNPs as coiled structures [46], there were small features at
the vicinity of the matrix that might correspond to vRNP (shown by
white arrow in Fig. 5C).
Table 1
List of peptides presenting BPL addition on assembled proteins.
(M+H)+ Sequence BPL number Complementary data
HA2 1806.8 FHQIEK68EFSEVEGR 1 Induced a miss cleavage (MC)
HA2 1778.8 IYHK143C⁎DNAC⁎IGSIR 1 MC and modiﬁed cysteine
M1 2923.4 MGAVTTEVAFGLVC⁎ATC⁎E152QIAD156SQH159R 1 Modiﬁed cysteine
Peptide sequence coverage was 73% for NP, 33% for HA1, 49% for HA2 and 80% for M1 proteins.
⁎ modiﬁed cysteine.
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by addition of amantadine unlike native virus
Monensin experiments suggested that the acidiﬁcation process of
the viral internal compartment was still a parameter of importance for
membrane fusion even after BPL treatment. We used amantadine
which blocks proton transport through the channel formed by M2
tetramer slowing down membrane fusion activity [34,47–49]. Native
and BPL-treated viruses were incubated with increasing amantadine
concentrations (10, 50 μg/mL) and FRET assays were performed at pH
5.1 (Fig. 6A). Increasing amantadine concentration progressively
inhibited the membrane fusion activity of native virus. For 1mM BPL-
treated virus, the fusion activity was lower than those of native virus
treated with amantadine. In addition, incubations of BPL-treated virus
with 10 and 50 μg/mL amantadine had no noticeable effect on
membrane fusion activity. Addition of amantadine does not reinforce
inhibition caused by BPL treatment indicating that M2 channel of BPL-
treated virus is not inhibited by amantadine at these concentrations.A
C
Fig. 5.Membrane fusion activity of BPL-treated virus enhanced in the presence ofmonensin. A) F
incubated without and with 1 μMmonensin (a*, b*) at 37 °C. B) CryoTEM of BPL-treated H3N2
observed. C, D) Six Z-slices extracted through a liposome (III) tomogram, and an enlarged 7.4nm
and yellow respectively. Elongated features resembling coiled structures (white arrow in C). S4. Discussion
Although employed to manufacture many millions of vaccine dosed
annually virus inactivation using BPL treatment remains a poorly
understood process. BPL was found to react with nucleophilic groups
(such as primary or secondary amines) of nucleic acids leading to
virus inactivation [19–23]. Molecular studies are required to determine
precisely the molecular and structural consequences of BPL action
which is an essential prerequisite to rationally optimize industrial
scale vaccine production processes.
A major ﬁnding of our work consists in the demonstration that viral
membrane fusion is altered after BPL treatment. Over a large con-
centration range from 2 μM to 1 mM BPL, this inhibition is dose-
dependent. However the membrane fusion process is not completely
abolished even at 1 mM BPL in good concordance with recent
observations on H5N1 virus samples inactivated with BPL [18].
The observed decreases of virus infectivity and membrane fusion
activity are both BPL dose dependent. FRET experiments show that thea
a*
b
b*
B
D
RET assaysmonitoringmembrane fusion of native (a) and1000μMBPL-treated (b) viruses
virus in the presence of 1 μMmonensin mixed with GM3 liposomes. Liposomes (III) were
slice depicting glycoproteins, lipid membrane, viral matrix manually colored in red, blue
cale bars are 50 nm.
AB
a
b
c
a*
b*,c*
NAHAM2
M1
Viral lipid 
membrane
(-) RNA strands 
Target lipid
membrane
Fig. 6. Amantadine effect on membrane fusion activity of native and BPL-treated virus.
A) FRET assays monitoring membrane fusion of native virus incubated with 0 (a), 10
(b) and 50μg/mL amantadine (c) at 37°C. Likewise, 1000μMBPL treated viruswas incubated
with 0 (a*), 10 (b*) and 50 μg/mL amantadine (c*) at 37 °C. B) Scheme of BPL mechanism of
action on inﬂuenza virus membrane fusion. Virus membrane including HA, NA, M1 and M2
proteins and vRNP have been schematically drawn. Virus inactivation relies on protein
modiﬁcations involved in membrane fusion process and on nucleic acids modiﬁcations.
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On the plot of virus infectivity against the fusion initial rate, a linear
regression function was observed between infectivity and initial rate
for BPL doses up to 250 μM (Fig. 2C). This direct correlation suggests
that at these BPL concentrations (from 2 to 250 μM), loss of infectivity
is strictly dependent on membrane fusion inhibition. This analysis
reveals that BPL concentrations superior to 250 μM BPL are sufﬁcient
for viral inactivation. This also could reﬂect that virus accessibility for
BPL molecules is related to a diffusion gradient across the viral
membrane. High BPL concentrations would be required to reach the
most buried parts of the virus such as vRNPs. Differences in BPL diffusion
within the virus may in part explain the differences reported in the
literature concerning the BPL doses required for viral inactivation
[22,23]. BPL efﬁciency may also depend on the corresponding
alterations of the viral structures. Our MS data show that among
investigated proteins (i.e. HA, M1, vRNP) relatively few amino acids
were modiﬁed. Even though BPL is reported very reactive on isolated
residues [26], the reaction of BPL on whole virus seems much more
limited. In the whole virus, proteins are folded into quaternary
structures with post-translational modiﬁcations such as glycosylationthat may restrain the reaction of their nucleophilic groups with BPL.
Interestingly, our mass spectrometric analysis reveals that the extent
of BPL protein modiﬁcation of deglycosylated virus is superior to
that of glycosylated viruses suggesting a protective role of protein
glycosylation (Table S1).
Our data also indicate that BPL could also alter the activity of viral
proteins. In terms of virus infectivity, NA (neuraminidase) can yet be
excluded from these potential candidates involved in BPL-inactivation
mechanism. Indeed, NA is essential for virus budding at the end of the
replication process in the host cell but not during the ﬁrst step of
inﬂuenza virus infection [8].
The HA1 domain exposes a binding domain to sialic acid while HA2
subunit contains the fusion peptide and undergoes conformational
changes triggering membrane fusion. Our MS results showed that HA2
domain was modiﬁed by BPL treatment. A modiﬁcation was depicted
on Lys68 of HA2 belonging to a loop which is structured into α helix
at low pH to lengthen the coiled coil, the post fusion structure proposed
by Bullough et al. [9]. The reduction of calcein release could be also
explained by the modiﬁcation of HA2. This modiﬁcation prevents the
conformational change and subsequently the insertion of fusion peptide
in target membrane [12]. Moreover, calcein leakage experiments
indicate that native and BPL-treated viruses have similar initial rates
suggesting that for HA remaining active, the mechanism triggering the
peptide insertion in the target membrane is not modiﬁed. Altogether,
these results suggest that a low BPL dose was enough for inactivating
fusion peptide of HA2. Surprisingly this inactivation did not affect all
HA2 proteins since this inhibition is not dose dependent and large
amount of HA2 proteins remains active even at higher BPL doses (albeit
this amount cannot be determined by ﬂuorescence). Although we do
not have clear explanation, it is worth noting that Lys residue can be
modiﬁed by BPL according to an alkylation or an acylation reaction [26].
The consequence is that acylation of Lys residues results in a neutral
moiety at low pH while alkylation results in a cationic secondary
amine and an anionic carboxylate. It is not excluded that this difference
in Lys modiﬁcation could lead to two populations of modiﬁed HA,
having either a full active or an inactive fusion peptide.
In addition to the effect on HA2, there is evidence that BPL treatment
affects other proteins involved in the process of membrane fusion. Our
MS results showed that M1 matrix was modiﬁed by BPL on several
amino acids located in the N-terminal domain of the matrix protein.
M1 consists of two N- and C-terminal domains which are both involved
in the oligomerization of M1. This oligomerization is pH sensitive and is
controlled by N-terminal domain which forms oligomer at pH 7.4 and
dissociates into monomer at pH5 [50]. On contrary, C-terminal domain
exists as stable dimer which contributes to M1 dimerization. As the BPL
modiﬁcation is located within the pH-sensitive N-terminal domain, it
cannot be excluded that thismodiﬁcation could perturbM1dissociation
at low pH, impairing membrane fusion. Amantadine experiments
revealed that membrane fusion of BPL-treated virus was not inhibited
by amantadine unlike untreated virus (Fig. 6A). Possible explanations
could be that amantadine has less afﬁnity for M2 channel after BPL-
treatment, or H+ transport has been modiﬁed. M2 channel seems also
to be affected by BPL treatment. As suggested for vRNP inactivation,
the BPL dose effect of membrane fusion activity is probably related to
the BPL accessibility suggesting that increasing the dose would modify
the most buried proteins. So the measured inhibition of membrane
fusion would probably arise from a cumulative inhibition on several
proteins rather than on a unique protein. Further MS experiments (i.e.
LC-ESI-MS) purposely designed to study M1 and M2 proteins are
needed.
5. Conclusion
In the present study, we showed that viral membrane fusion is
altered after BPL treatment. BPL treatment affects the function of HA
by preventing the insertion of its fusion peptide into target membrane,
363P. Bonnafous et al. / Biochimica et Biophysica Acta 1838 (2014) 355–363unveiling in more details the action of BPL (Fig. 6B). It is likely that an
additional vRNPs inactivation could provide a cumulative effect allowing
the complete abolishment of virus infectivitymeasured onMDCK cells at
high BPL doses. Further experiments are required to study BPL effects
on the other components of virus such as the other proteins and vRNPs
for a complete understanding of the BPL chemical mechanism of virus
inactivation.Acknowledgments
We would like to thank Toon Stegmann and Tino Krell for critical
reading and comments, Catherine Manin for mass spectrometry
expertise, Alain Brisson for equipment support and Sophie Bufﬁn for
experimental assistance.
This work was supported by Conseil Regional d'Aquitaine
(20071302007) (to OL).Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamem.2013.09.021.References
[1] A. Harris, G. Cardone, D.C. Winkler, J.B. Heymann, M. Brecher, J.M. White, A.C.
Steven, Inﬂuenza virus pleiomorphy characterized by cryoelectron tomography,
Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 19123–19127.
[2] W. Weis, J.H. Brown, S. Cusack, J.C. Paulson, J.J. Skehel, D.C. Wiley, Structure of the
inﬂuenza virus haemagglutinin complexed with its receptor, sialic acid, Nature
333 (1988) 426–431.
[3] S.C. Harrison, Viral membrane fusion, Nat. Struct. Mol. Biol. 15 (2008) 690–698.
[4] M. Knossow, J.J. Skehel, Variation and infectivity neutralization in inﬂuenza,
Immunology 119 (2006) 1–7.
[5] J.J. Skehel, D.C. Wiley, Receptor binding and membrane fusion in virus entry: the
inﬂuenza hemagglutinin, Annu. Rev. Biochem. 69 (2000) 531–569.
[6] T. Stegmann,Membrane fusionmechanisms: the inﬂuenza hemagglutinin paradigm
and its implications for intracellular fusion, Trafﬁc 1 (2000) 598–604.
[7] I.A. Wilson, J.J. Skehel, D.C. Wiley, Structure of the haemagglutinin membrane
glycoprotein of inﬂuenza virus at 3 A resolution, Nature 289 (1981) 366–373.
[8] S.J. Gamblin, J.J. Skehel, Inﬂuenza hemagglutinin and neuraminidase membrane
glycoproteins, J. Biol. Chem. 285 (2010) 28403–28409.
[9] P.A. Bullough, F.M. Hughson, J.J. Skehel, D.C. Wiley, Structure of inﬂuenza
haemagglutinin at the pH of membrane fusion, Nature 371 (1994) 37–43.
[10] T. Stegmann, J.M. Delﬁno, F.M. Richards, A. Helenius, The HA2 subunit of inﬂuenza
hemagglutinin inserts into the target membrane prior to fusion, J. Biol. Chem. 266
(1991) 18404–18410.
[11] M. Tsurudome, R. Glück, R. Graf, R. Falchetto, U. Schaller, J. Brunner, Lipid
interactions of the hemagglutinin HA2 NH2-terminal segment during inﬂuenza
virus-induced membrane fusion, J. Biol. Chem. 267 (1992) 20225–20232.
[12] P. Bonnafous, T. Stegmann, Membrane perturbation and fusion pore formation in
inﬂuenza hemagglutinin-mediated membrane fusion A new model for fusion, J.
Biol. Chem. 275 (2000) 6160–6166.
[13] A.L. Lai, L.K. Tamm, Shallow boomerang-shaped inﬂuenza hemagglutinin G13A
mutant structure promotes leaky membrane fusion, J. Biol. Chem. 285 (2010)
37467–37475.
[14] L.V. Chernomordik, V.A. Frolov, E. Leikina, P. Bronk, J. Zimmerberg, The pathway of
membrane fusion catalyzed by inﬂuenza hemagglutinin: restriction of lipids,
hemifusion, and lipidic fusion pore formation, J. Cell Biol. 140 (1998) 1369–1382.
[15] K.K. Lee, Architecture of a nascent viral fusion pore, EMBO J. 29 (2010) 1299–1311.
[16] K.Martin, A.Helenius, Nuclear transport of inﬂuenzavirus ribonucleoproteins: the viral
matrix protein (M1) promotes export and inhibits import, Cell 67 (1991) 117–130.
[17] M. Lakadamyali, M.J. Rust, X. Zhuang, Endocytosis of inﬂuenza viruses, Microbes
Infect. 6 (2004) 929–936.
[18] N. Budimir, A. Huckriede, T. Meijerhof, L. Boon, E. Gostick, D.A. Price, J. Wilschut, A.
de Haan, Induction of heterosubtypic cross-protection against inﬂuenza by a
whole inactivated virus vaccine: the role of viral membrane fusion activity, PLoS
ONE 7 (2012) e30898.
[19] E.I. Budowsky, E.A. Friedman, N.V. Zheleznova, Principles of selective inactivation of
viral genome VII. Some peculiarities in determination of viral suspension infectivity
during inactivation by chemical agents, Vaccine 9 (1991) 473–476.
[20] E.I. Budowsky, E.A. Friedman, N.V. Zheleznova, F.S. Noskov, Principles of selective
inactivation of viral genome VI Inactivation of the infectivity of the inﬂuenza virus
by the action of beta-propiolactone, Vaccine 9 (1991) 398–402.[21] E.I. Budowsky, Y.A. Smirnov, S.F. Shenderovich, Principles of selective inactivation of
viral genome. VIII. The inﬂuence of beta-propiolactone on immunogenic and
protective activities of inﬂuenza virus, Vaccine 11 (1993) 343–348.
[22] P. Perrin, S. Morgeaux, Inactivation of DNA by beta-propiolactone, Biologicals 23
(1995) 207–211.
[23] A. Scheidler, K. Rokos, T. Reuter, R. Ebermann, G. Pauli, Inactivation of viruses by
beta-propiolactone in human cryo poor plasma and IgG concentrates, Biologicals
26 (1998) 135–144.
[24] P.D. Bartlett, G. Small, beta-Propiolactone IX the kinetics of attack by nucleophilic
reagents upon the alcoholic carbon of p-propiolactone, J. Am. Chem. Soc. 72
(1950) 4867–4869.
[25] M.A. Taubman, M.Z. Atassi, Reaction of beta-propiolactone with amino acids and its
speciﬁcity for methionine, Biochem. J. 106 (1968) 829–834.
[26] J.P. Uittenbogaard, B. Zomer, P. Hoogerhout, B. Metz, Reactions of beta-
propiolactone with nucleobase analogues, nucleosides, and peptides: implications
for the inactivation of viruses, J. Biol. Chem. 286 (2011) 36198–36214.
[27] M. Shaﬁque, J. Wilschut, A. de Haan, Induction of mucosal and systemic immunity
against respiratory syncytial virus by inactivated virus supplemented with TLR9
and NOD2 ligands, Vaccine 30 (2012) 597–606.
[28] C.J.F. Böttcher, C.M. Van gent, C. Pries, A rapid and sensitive sub-micro phosphorus
determination, Anal. Chim. Acta. 24 (1961) 203–204.
[29] B. Desbat, E. Lancelot, T. Krell, M.-C. Nicolaï, F. Vogel, M. Chevalier, F. Ronzon,
Effect of the β-propiolactone treatment on the adsorption and fusion of
inﬂuenza A/Brisbane/59/2007 and A/New Caledonia/20/1999 Virus H1N1 on a
dimyristoylphosphatidylcholine/Ganglioside GM3 mixed phospholipids monolayer
at the air–water interface, Langmuir 27 (2011) 13675–13683.
[30] A. Roberts, E.W. Lamirande, L. Vogel, B. Baras, G. Goossens, I. Knott, J. Chen, J.M.
Ward, V. Vassilev, K. Subbarao, Immunogenicity and protective efﬁcacy in mice
and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine,
Viral Immunol. 23 (2010) 509–519.
[31] D.J. Finney, Statistical method in biological assay, 1952.
[32] D.K. Struck, D. Hoekstra, R.E. Pagano, Use of resonance energy transfer to monitor
membrane fusion, Biochemistry 20 (1981) 4093–4099.
[33] T. Stegmann, D. Hoekstra, G. Scherphof, J. Wilschut, Kinetics of pH-dependent fusion
between inﬂuenza virus and liposomes, Biochemistry 24 (1985) 3107–3113.
[34] R. Bron, A.P. Kendal, H.D. Klenk, J. Wilschut, Role of theM2 protein in inﬂuenza virus
membrane fusion: effects of amantadine and monensin on fusion kinetics, Virology
195 (1993) 808–811.
[35] S.A. Wharton, R.B. Belshe, J.J. Skehel, A.J. Hay, Role of virion M2 protein in inﬂuenza
virus uncoating: speciﬁc reduction in the rate of membrane fusion between virus
and liposomes by amantadine, J. Gen. Virol. 75 (Pt 4) (1994) 945–948.
[36] Q.S. Zheng, M.B. Braunfeld, J.W. Sedat, D.A. Agard, An improved strategy for
automated electron microscopic tomography, J. Struct. Biol. 147 (2004) 91–101.
[37] D.N. Mastronarde, Dual-axis tomography: an approach with alignment methods
that preserve resolution, J. Struct. Biol. 120 (1997) 343–352.
[38] H. Chen, D.D. Hughes, T.A. Chan, J.W. Sedat, D.A. Agard, IVE (Image Visualization
Environment): a software platform for all three-dimensional microscopy applications,
J. Struct. Biol. 116 (1996) 56–60.
[39] E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, T.E.
Ferrin, UCSF Chimera—a visualization system for exploratory research and analysis,
J. Comput. Chem. 25 (2004) 1605–1612.
[40] T. Stegmann, J.M. White, A. Helenius, Intermediates in inﬂuenza induced membrane
fusion, EMBO J. 9 (1990) 4231–4241.
[41] T. Shangguan, D. Alford, J. Bentz, Inﬂuenza–virus–liposome lipid mixing is leaky and
largely insensitive to the material properties of the target membrane, Biochemistry
35 (1996) 4956–4965.
[42] R. Jiricek, G. Schwarz, T. Stegmann, Pores formed by inﬂuenza hemagglutinin,
Biochim. Biophys. Acta 1330 (1997) 17–28.
[43] Y. Li, X. Han, A.L. Lai, J.H. Bushweller, D.S. Caﬁso, L.K. Tamm, Membrane structures of
the hemifusion-inducing fusion peptide mutant G1S and the fusion-blocking
mutant G1V of inﬂuenza virus hemagglutinin suggest a mechanism for pore
opening in membrane fusion, J. Virol. 79 (2005) 12065–12076.
[44] P. Bonnafous, M. Perrault, O. Le Bihan, B. Bartosch, D. Lavillette, F. Penin, O. Lambert,
E.-I. Pécheur, Characterization of hepatitis C virus pseudoparticles by cryo-
transmission electron microscopy using functionalized magnetic nanobeads, J.
Gen. Virol. 91 (2010) 1919–1930.
[45] L.J. Calder, S. Wasilewski, J.A. Berriman, P.B. Rosenthal, Structural organization of a
ﬁlamentous inﬂuenza A virus, Proc. Natl. Acad. Sci. U. S. A. 107 (2010) 10685–10690.
[46] T. Noda, H. Sagara, A. Yen, A. Takada, H. Kida, R.H. Cheng, Y. Kawaoka, Architecture of
ribonucleoprotein complexes in inﬂuenza A virus particles, Nature 439 (2006)
490–492.
[47] S.D. Cady, K. Schmidt-Rohr, J. Wang, C.S. Soto, W.F. Degrado, M. Hong, Structure of
the amantadine binding site of inﬂuenza M2 proton channels in lipid bilayers,
Nature 463 (2010) 689–692.
[48] M. Sharma, C. Li, D.D. Busath, H.-X. Zhou, T.A. Cross, Drug sensitivity, drug-resistant
mutations, and structures of three conductance domains of viral porins, Biochim.
Biophys. Acta 1808 (2011) 538–546.
[49] M. Sharma, M. Yi, H. Dong, H. Qin, E. Peterson, D.D. Busath, H.-X. Zhou, T.A. Cross,
Insight into the mechanism of the inﬂuenza A proton channel from a structure in
a lipid bilayer, Science 330 (2010) 509–512.
[50] K. Zhang, Z.Wang, X. Liu, C. Yin, Z. Basit, B. Xia,W. Liu, Dissection of inﬂuenza A virus
M1 protein: pH-dependent oligomerization of N-terminal domain and dimerization
of C-terminal domain, PLoS ONE 7 (2012) e37786.
